Table 5.
Subgroup analyses (CBR)
| N | Overall (N = 88) | N | Standard (N = 40) | N | Bi-weekly (N = 42) | |
|---|---|---|---|---|---|---|
| All | 88 | 23 (26.1) | 40 | 10 (25.0) | 42 | 13 (31.0) |
| Hormone receptor status (ER and/or PgR) | ||||||
| Positive | 54 | 16 (29.6) | 23 | 7 (30.4) | 27 | 9 (33.3) |
| Negative | 34 | 7 (20.6) | 17 | 3 (17.6) | 15 | 4 (26.7) |
| No. of chemotherapy regimens for advanced or MBC | ||||||
| 0 | 15 | 7 (46.7) | 5 | 2 (40.0) | 9 | 5 (55.6) |
| 1 | 23 | 4(17.4) | 14 | 2 (14.3) | 8 | 2(25.0) |
| 2 | 27 | 7 (25.9) | 10 | 4 (40.0) | 14 | 3 (21.4) |
| 3 | 23 | 5(21.7) | 11 | 2 (18.2) | 11 | 3 (27.3) |
| Relative dose intensity | ||||||
| > 75% | 50 | 10 (20.0) | 36 | 9 (25.0) | 8 | 1 (12.5) |
| < 75% | 38 | 13 (34.2) | 4 | 1 (25.0) | 34 | 12 (35.3) |
| Neutropenia (cycle 1, day 8) | ||||||
| > 1000 | 57 | 15 (26.3) | 39 | 10 (25.6) | 14 | 5 (35.7) |
| < 1000 | 30 | 8 (26.7) | 0 | 0 (0.0) | 28 | 8 (28.6) |
| Age | ||||||
| ≥ 65 | 26 | 9 (34.6) | 14 | 5 (35.7) | 12 | 4 (33.3) |
| < 65 | 56 | 15 (26.8) | 26 | 5 (19.2) | 30 | 9 (30.0) |
CBR clinical benefit rate, ER estrogen receptor, PgR progesterone receptor, MBC metastatic breast cancer